Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

  title={Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.},
  author={Juan Pablo Frias and Melanie Jane Davies and Julio Rosenstock and Federico C. P{\'e}rez Manghi and Laura Fern{\'a}ndez Land{\'o} and Brandon Bergman and Bing Liu and Xuewei Cui and Katelyn Brown},
  journal={The New England journal of medicine},
BACKGROUND Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or… 
The emerging role of incretins and twincretins
Tirzepatide (a new dual GIP–GLP1 receptor agonist based on the native GIP sequence) was associated with up to 2% reduction in HbA 1c and a dose-dependent reduction in body weight in patients with type 2 diabetes mellitus, and was superior to semaglutide in head-to-head comparisons in reducing Hb a1c and body weight.
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
To assess the efficacy and safety of tirzepatide added to insulin glargine in patients with type 2 diabetes with inadequate glycemic control, a Randomized phase 3 clinical trial was conducted at 45 medical research centers and hospitals in 8 countries.
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Tirzepatide pharmacokinetics was similar in participants with varying degrees of hepatic impairment compared with healthy participants, and people with hepatic impairments treated with tirzep atide may not require dose adjustments.
The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
This review summarizes the body weight reduction efficacy, glycemic control, and safety of semaglutide up to a 2.4-mg dose and tirzepatide up for a 15-mg doses, focusing on the SemaglUTide Treatment Effect in People with Obesity trials, the subjects of which were all patients with type 2 diabetes mellitus.
Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
Tirzepatide significantly improved glycemic control and body weight and had an acceptable safety profile, indicating that it is an effective therapeutic option for glucose-lowering in patients with type 2 diabetes mellitus.
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
A dose-dependent superiority on glycaemic efficacy and body weight reduction was evident with tirzepatide vs placebo, GLP-1 RAs and basal insulin and all tirzEPatide doses were safe in terms of serious adverse events and mortality.
The dawning of dual-acting incretin drugs
Two phase III clinical trials report efficacy and safety findings of a novel dual-acting glucose-dependent insulinotropic polypeptide (GIP) and GLP1 receptor agonist — tirzepatide — in patients with type 2 diabetes mellitus and concluded that tirzEPatide at all doses was noninferior and superior to semaglutide with respect to the mean change in HbA1c over 40 weeks.